AEON Biopharma (AEON) to Release Quarterly Earnings on Monday

AEON Biopharma (NASDAQ:AEON) is expected to announce its earnings results before the market opens on Monday, August 11th. Analysts expect the company to announce earnings of ($11.51) per share for the quarter.

AEON Biopharma Stock Performance

AEON Biopharma stock opened at $0.70 on Friday. The stock has a fifty day moving average of $0.78 and a two-hundred day moving average of $2.05. The company has a market capitalization of $7.95 million, a price-to-earnings ratio of 3.91 and a beta of 0.71. AEON Biopharma has a fifty-two week low of $0.38 and a fifty-two week high of $115.57.

Insiders Place Their Bets

In related news, Director Jost Fischer purchased 60,000 shares of the company’s stock in a transaction on Tuesday, May 20th. The stock was bought at an average price of $0.51 per share, with a total value of $30,600.00. Following the completion of the transaction, the director owned 206,785 shares of the company’s stock, valued at approximately $105,460.35. This represents a 40.88% increase in their position. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Insiders own 0.86% of the company’s stock.

AEON Biopharma Company Profile

AEON Biopharma, Inc, a clinical stage biopharmaceutical company, focuses on developing botulinum toxins. It develops ABP-450 (prabotulinumtoxinA) injection for debilitating medical conditions, which completed Phase 2 study for the treatment of cervical dystonia and has an ongoing Phase 2 study for the treatment of both chronic and episodic migraine, as well as develops ABP-450 for the treatment of gastroparesis and posttraumatic stress disorder.